Triumph New Energy (01108) received the administrative regulatory measures decision from the Henan Regulatory Bureau of the China Securities Regulatory Commission.
Kaisheng New Energy (01108) announced that the company recently received the "Decision on Administrative Supervisory Measures" ([2026] No. 37) issued by the China Securities Regulatory Commission Henan Supervision Bureau (Henan Supervision Bureau) (warning letter). The content of the warning letter is summarized as follows:
Triumph New Energy (01108) has announced that the company recently received an "Administrative Supervision Measure Decision" ([2026] No. 37) issued by the Henan Supervision Bureau of the China Securities Regulatory Commission (CSRC) (hereinafter referred to as the Henan Supervision Bureau). The content of the warning letter is summarized as follows:
The Henan Supervision Bureau found the following issues with the company:
The company has accumulated a total litigation and arbitration amount of 333 million yuan over 12 consecutive months, which reached 10.73% of the absolute value of the latest audited net assets. The company only made supplementary disclosures by June 29, 2026, which caused relevant information to be disclosed in a timely manner and violated Article 80, Paragraph 2, Item 10 of the "Securities Law of the People's Republic of China," as well as Article 3, Paragraph 1 and Article 23, Paragraph 2, Item 1 of the "Regulations on the Management of Information Disclosure by Listed Companies" (CSRC Order No. 226).
The Henan Supervision Bureau believes that Xie Jun, as the chairman of the company, Chen Peng, as the general manager, and Chen Hongzhao, as the secretary of the board, have not diligently fulfilled their responsibilities and bear primary responsibility for the above-mentioned matters, which violates Article 4 and Paragraph 2 of Article 52 of the "Regulations on the Management of Information Disclosure by Listed Companies."
In accordance with Article 53 of the "Regulations on the Management of Information Disclosure by Listed Companies," the Henan Supervision Bureau decided to issue a warning letter to the company and to Xie Jun, Chen Peng, and Chen Hongzhao as a supervisory measure, which will be recorded in the integrity archive of the securities and futures market. The Henan Supervision Bureau reminds the relevant personnel to fully learn from this lesson, strengthen the study of securities laws and regulations, take effective measures to enhance internal control and management of information disclosure affairs, and effectively improve the company's operational standards and the quality of information disclosure. A written rectification report should be submitted to the Henan Supervision Bureau within 15 working days from the date of receipt of the decision letter.
If there are objections to the above-mentioned supervisory measures, an application for administrative reconsideration may be submitted to the China Securities Regulatory Commission within 60 days from the date of receipt of the decision letter, or a lawsuit may be filed in a competent people's court within 6 months from the date of receipt of the decision letter. During the reconsideration and litigation period, the above-mentioned supervisory measures will remain in effect.
The board of directors believes that the supervisory measures contained in the warning letter will not affect the company's normal business management activities. The company and relevant personnel will take the issues pointed out in the warning letter seriously, learn from this lesson, and adopt effective measures to strengthen internal control and information disclosure management, strictly fulfill information disclosure obligations as required, and effectively enhance the level of internal control and management of information disclosure in the company.
Related Articles
HANSOH PHARMA (03692): HS-10582 tablets have received the clinical trial approval notice issued by the National Medical Products Administration.

UBOT HOLDING (08529) has issued a profit warning, expecting a mid-term net profit of approximately HKD 11 million, an increase of over 100% year-on-year.

On August 6, XD INC (02400) spent approximately HKD 4.948 million to repurchase 110,000 shares.
HANSOH PHARMA (03692): HS-10582 tablets have received the clinical trial approval notice issued by the National Medical Products Administration.
UBOT HOLDING (08529) has issued a profit warning, expecting a mid-term net profit of approximately HKD 11 million, an increase of over 100% year-on-year.

On August 6, XD INC (02400) spent approximately HKD 4.948 million to repurchase 110,000 shares.

RECOMMEND





